伐度司他(Vadadustat)现在多少钱可以买到

Vadadustat is an oral HIF-PH inhibitor, mainly used to treat anemia in patients with dialysis-dependent chronic kidney disease. It improves anemia by regulating erythropoietin (EPO) and iron metabolism.

How much can you buy Vadadustat now?

Vadadustat has not yet been approved for marketing in mainland China, and patients cannot purchase it directly through local medical institutions. The original drug is produced by MEDICE in Germany, and the price and specifications are as follows:

Specifications and Prices

The original drug produced by MEDICE in Germany has a specification of 300mg*98 tablets/box, and the price is about US$320. There are currently no generic drugs on the market, and patients need to pay the full amount out of their own pocket. For patients who require long-term medication, it is recommended to plan the drug purchase cycle in advance to avoid delays in logistics that may affect treatment.

Why are original drugs expensive?

The higher prices of original drugs are mainly related to research and development costs, patent protection and production standards. As an innovative drug, vadostat requires huge investment in clinical trials and must comply with international GMP certification standards.

You need to provide a doctor's prescription when purchasing, and purchase through a compliant cross-border medical platform. It is recommended to choose a platform that provides drug traceability services to ensure that the production batch number and expiration date of each box of drugs can be queried.

Usage and dosage of Vadadustat

The correct use of Vadadustat is crucial to controlling the progression of anemia and reducing the risk of side effects. The following are medication recommendations:

Pre-treatment assessment and preparation

Before starting treatment, other causes of anemia, such as iron deficiency, vitamin deficiency or chronic inflammation, need to be ruled out, and serum ferritin (target ≥100mcg/L) and transferrin saturation (≥20%) should be measured. If the target is not reached, iron supplements need to be supplemented first, and a baseline liver function test must be completed to ensure that there is no active liver disease.

Recommended starting dose

The starting dose for adult patients, regardless of whether they have received erythropoiesis stimulating agents, is 300 mg orally daily. Tablets should be swallowed whole and should not be cut or chewed. If you miss a dose, you do not need to take it again. You can continue taking the medicine as originally planned the next day. Hemoglobin needs to be monitored regularly during treatment, and the target value is ≤11g/dL.

When the Hb rising rate is >1g/dL/2 weeks or >2g/dL/4 weeks, the medication needs to be suspended. After Hb falls back to the target value, reduce the dose by 150 mg and resume. If there is no significant improvement in Hb within 24 weeks, the drug needs to be discontinued and the cause re-evaluated

Special medication groups for Vadadustat

Some patients need to be particularly cautious when using vadadustat. The following are recommendations for special groups:

Pregnant and lactating women

Animal studies show high dosesValostat may affect fetal development and should only be used by pregnant women when the benefits are clear and the risks are controllable. Breastfeeding women need to suspend breastfeeding until 2 days after the last dose to avoid drug transfer through breast milk.

Children and Adolescents

The safety and effectiveness of vadostat in people under 18 years of age have not been established. It is not recommended for children. Adolescent patients need to strictly evaluate the necessity of treatment under the guidance of a doctor.

Elderly patients and patients with liver disease

Patients over 65 years old do not need to adjust the dosage, but they need to strengthen cardiovascular and liver function monitoring. It is contraindicated in patients with cirrhosis or acute liver disease. Patients with Child-Pugh B class do not need to reduce the dose, but liver function indicators need to be tested monthly.

Valdostat needs to be stored in a dark environment at 20–25°C, keeping the original packaging sealed. After opening, the bottle should be placed in a dry place to avoid high temperature or humid environment.